Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

    Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML.

    Cancer Res. 2012 Mar 15;72(6):1529-37. Epub 2012 Jan 26.

    PMID:
    22282656
    [PubMed - indexed for MEDLINE]
    2.

    ARN-509: a novel antiandrogen for prostate cancer treatment.

    Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

    Cancer Res. 2012 Mar 15;72(6):1494-503. Epub 2012 Jan 20.

    PMID:
    22266222
    [PubMed - indexed for MEDLINE]
    3.

    Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

    Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

    Cancer Res. 2012 Feb 1;72(3):616-25. Epub 2011 Dec 7.

    PMID:
    22158653
    [PubMed - indexed for MEDLINE]
    4.

    Error occurred: cannot get document summary

    PMID:
    22127922

    5.

    Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

    Rowlands MA, Holly JM, Gunnell D, Donovan J, Lane JA, Hamdy F, Neal DE, Oliver S, Smith GD, Martin RM.

    Cancer Res. 2012 Jan 15;72(2):503-15. Epub 2011 Nov 21.

    PMID:
    22106399
    [PubMed - indexed for MEDLINE]
    6.

    Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.

    Song JH, Kraft AS.

    Cancer Res. 2012 Jan 1;72(1):294-303. Epub 2011 Nov 11.

    PMID:
    22080570
    [PubMed - indexed for MEDLINE]
    7.

    GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.

    Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC.

    Cancer Res. 2011 Dec 15;71(24):7694-704. Epub 2011 Oct 24.

    PMID:
    22025562
    [PubMed - indexed for MEDLINE]
    8.

    Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.

    Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J.

    Cancer Res. 2011 Dec 15;71(24):7525-36. Epub 2011 Oct 17.

    PMID:
    22007000
    [PubMed - indexed for MEDLINE]
    9.

    LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells.

    Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, Kelly K.

    Cancer Res. 2011 Dec 1;71(23):7301-11. Epub 2011 Oct 6.

    PMID:
    21978933
    [PubMed - indexed for MEDLINE]
    10.

    Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

    Jiang ZK, Sato M, Wei LH, Kao C, Wu L.

    Cancer Res. 2011 Oct 1;71(19):6250-60. Epub 2011 Sep 20.

    PMID:
    21933883
    [PubMed - indexed for MEDLINE]
    11.

    Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.

    Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP.

    Cancer Res. 2011 Sep 15;71(18):5987-97. Epub 2011 Sep 6.

    PMID:
    21896641
    [PubMed - indexed for MEDLINE]
    12.

    Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation.

    Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J.

    Cancer Res. 2011 Nov 1;71(21):6817-26. Epub 2011 Sep 8.

    PMID:
    21903767
    [PubMed - indexed for MEDLINE]
    13.

    Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.

    Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W, Wang Q.

    Cancer Res. 2011 Nov 1;71(21):6738-48. Epub 2011 Sep 7. Erratum in: Cancer Res. 2011 Dec 15;71(24):7718.

    PMID:
    21900400
    [PubMed - indexed for MEDLINE]
    14.

    Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.

    Smith HA, Cronk RJ, Lang JM, McNeel DG.

    Cancer Res. 2011 Nov 1;71(21):6785-95. Epub 2011 Aug 31.

    PMID:
    21880588
    [PubMed - indexed for MEDLINE]
    15.

    Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

    Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

    Cancer Res. 2011 Oct 15;71(20):6503-13. Epub 2011 Aug 25.

    PMID:
    21868758
    [PubMed - indexed for MEDLINE]
    16.

    TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.

    Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, Chinnaiyan AM.

    Cancer Res. 2011 Aug 15;71(16):5387-92. Epub 2011 Jun 15.

    PMID:
    21676887
    [PubMed - indexed for MEDLINE]
    17.

    BMP4 promotes prostate tumor growth in bone through osteogenesis.

    Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH.

    Cancer Res. 2011 Aug 1;71(15):5194-203. Epub 2011 Jun 13.

    PMID:
    21670081
    [PubMed - indexed for MEDLINE]
    18.

    Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.

    Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, Brinkmann K, Dirmeier U, Laus R, Delcayre A.

    Cancer Res. 2011 Aug 1;71(15):5235-44. Epub 2011 Jun 13.

    PMID:
    21670078
    [PubMed - indexed for MEDLINE]
    19.

    18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

    Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK.

    Cancer Res. 2011 Aug 1;71(15):5164-74. Epub 2011 Jun 6.

    PMID:
    21646475
    [PubMed - indexed for MEDLINE]
    20.

    Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

    Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

    Cancer Res. 2011 Sep 15;71(18):6019-29. Epub 2011 Jul 28.

    PMID:
    21799031
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk